Publications by authors named "R Bruno Bossio"

Article Synopsis
  • The study investigates the relationship between the prescription of Alzheimer's symptomatic drugs and the actual number of dementia patients in Italy, alongside the effect of treatment adherence on the use of additional medications for dementia-related symptoms.
  • Involving over 84,000 individuals aged 60 and older, the research reveals that nearly half of those treated with acetylcholinesterase inhibitors (AChEI) or memantine adhere to treatment, while many dementia diagnoses occur at advanced stages.
  • Results indicate that adherence to AChEI or memantine does not significantly alter the prescription patterns for antipsychotics and antidepressants, though higher non-steroidal anti-inflammatory drug use is noted among non-adherent patients, highlighting potential gaps in chronic pain
View Article and Find Full Text PDF

Background: Subcutaneous recombinant interferon-beta 1a (IFN-β1a SC) is indicated for treatment of relapsing multiple sclerosis (RMS); however, it is associated with development of flu-like syndrome (FLS) in 75% of patients. No recommendations are available on whether evening or morning administration could induce better or worse FLS.

Objective: Primary objective was to investigate whether morning administration of IFN-β1a 44 µg (Rebif) would affect the severity of FLS versus evening administration, in patients with RMS.

View Article and Find Full Text PDF
Article Synopsis
  • * In this study, two methods were used to look at the speech of 153 people, including healthy folks and patients with Parkinson's Disease and Multiple Sclerosis, to see how their voices were different.
  • * Results show that certain voice features can help doctors understand and diagnose speech problems better, making it easier to watch how diseases like Parkinson's and Multiple Sclerosis affect patients.
View Article and Find Full Text PDF

Background: Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS).

Objectives: We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF.

Materials And Methods: A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy.

View Article and Find Full Text PDF

Background: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment.

Methods: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs.

View Article and Find Full Text PDF